Leerink downgraded Avadel Pharmaceuticals (AVDL) to Market Perform from Outperform with an $18.50 price target after the company agreed to be acquired by Alkermes (ALKS) for for $18.50 per share upfront along with a non-transferable contingent value right entitling holders to a potential additional cash payment of $1.50 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Alkermes price target raised to $45 from $38 at Piper Sandler
- Alkermes price target raised to $47 from $45 at RBC Capital
- Midday Fly By: Netflix, TI reports weigh on markets
- Avadel Pharmaceuticals downgraded to Neutral from Overweight at Piper Sandler
- Avadel Pharmaceuticals downgraded to Hold from Buy at Craig-Hallum